Sunshine Biopharma, Inc. (SBFM)
Nasdaq · Healthcare · Drug Manufacturers - Specialty & Generic
$0.4201−36.97%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $1.8M
- 52-week range
- $0.4117 – $24.30
- 52-week change
- −96.02%
- EPS (trailing)
- −$9.45
Fiscal year to Dec 2025
- Revenue
- $36.3M (+4.11%)
- Net income
- −$6.0M
- Operating margin
- −17.2%
- Free cash flow
- −$5.5M
From the company’s annual report on SEC EDGAR.
About Sunshine Biopharma, Inc.
Sunshine Biopharma, Inc. operates as a pharmaceutical company that engages in the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada. The company is developing SBFM-PL4, a protease inhibitor for the treatment of SARS coronavirus infections; and K1.1 mRNA, a lipid nano-particle for liver cancer. It also offers Essential 9, an amino acids capsules; Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name; and L-Citrulline and Taurine products. In addition, the company provides various generic prescription drugs for osteoporosis, cardiovascular, antipsychotic, antibacterial, hypertension, anti-inflammatory, allergy, antibiotic, central nervous system, diabetes, urology, antifungal, antimalarial, oncology, gastroenterology, dermatology, smoking cessation, cholelithiasis, anticonvulsant, urology, women's health, acid reflux, and anticonvulsant indications. Sunshine The company is based in Fort Lauderdale, Florida.
Headquarters: Fort Lauderdale, United States · 50 employees · sunshinebiopharma.com